Acumen Pharmaceuticals, Inc.
ABOS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | -$102,329 | -$52,371 | -$42,856 | -$100,606 |
| Dep. & Amort. | $178 | $184 | $169 | $4 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $9,635 | $6,145 | $3,061 | $922 |
| Change in WC | $11,653 | $3,866 | $3,986 | $298 |
| Other Non-Cash | -$5,352 | -$888 | $487 | $81,421 |
| Operating Cash Flow | -$86,215 | -$43,064 | -$35,153 | -$17,961 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$16 | -$21 | -$161 | -$40 |
| Net Acquisitions | $0 | $3 | -$39 | $0 |
| Inv. Purchases | -$170,731 | -$250,634 | -$41,514 | -$104,080 |
| Inv. Sales/Matur. | $218,774 | $78,981 | $80,860 | $0 |
| Other Inv. Act. | $0 | $0 | $39 | $0 |
| Investing Cash Flow | $48,027 | -$171,671 | $39,185 | -$104,120 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$739 | $30,000 | $0 | $0 |
| Stock Issued | $7,938 | $121,904 | $3,792 | $168,556 |
| Stock Repurch. | -$41 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 |
| Other Fin. Act. | -$230 | -$151 | $115 | $31,910 |
| Financing Cash Flow | $6,928 | $151,753 | $3,907 | $200,466 |
| Forex Effect | $0 | $0 | $0 | $0 |
| Net Chg. in Cash | -$31,260 | -$62,982 | $7,939 | $78,385 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $67,119 | $130,101 | $122,162 | $43,777 |
| End Cash | $35,859 | $67,119 | $130,101 | $122,162 |
| Free Cash Flow | -$86,231 | -$43,085 | -$35,314 | -$18,001 |